{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:54:54Z","timestamp":1774533294616,"version":"3.50.1"},"reference-count":148,"publisher":"Bentham Science Publishers Ltd.","issue":"18","funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology (DBT), Government of India","doi-asserted-by":"publisher","award":["BT\/PR30082\/Med\/29\/1341\/2018"],"award-info":[{"award-number":["BT\/PR30082\/Med\/29\/1341\/2018"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board, Department of Science and Technology, Government of India","doi-asserted-by":"publisher","award":["SR\/S2\/JCB-80)\/2012"],"award-info":[{"award-number":["SR\/S2\/JCB-80)\/2012"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2023,8,7]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>The chronic infection of the hepatitis B virus (CHB) represents a major public health problem worldwide. Despite the availability of an effective prophylactic vaccine, millions of hepati-tis B patients are at increased risk of developing chronic liver disease. The currently available treatments for HBV infection include interferon and nucleos(t)ide analogues that are effective at suppressing viral load and preventing or delaying the progression of liver disease. However, these treatments offer somewhat unsatisfactory clinical cures due to the persistence of the intrahepatic pool of covalently closed circular DNA (cccDNA) that serves as a reservoir for viral progenies and a potential source of recurring infections. Elimination of viral cccDNA remains a challenge for sci-entists and pharmaceutical industries in order to achieve the eradication and control of HBV infec-tion. This would involve a detailed understanding of the molecular mechanisms of cccDNA for-mation, its intracellular stability, and regulation during replication and transcription. Recent ad-vances in drug therapy have heralded a new horizon of novel therapeutic approaches for CHB infec-tion, with several promising antiviral and immunomodulatory agents currently in preclinical or clin-ical testing. However, approval of any new curative therapy would involve rigorous evaluation of the efficacy and safety of each treatment and defining correct endpoints associated with improved clinical outcomes. This article summarizes the current landscape of HBV treatments, and drugs in clinical trials and highlights the most recent anti-HBV small molecules designed to directly target HBV or to improve immune response during chronic infection.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026623666230413094331","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T04:04:41Z","timestamp":1681790681000},"page":"1727-1752","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Chronic Hepatitis B Infection: Current and Emerging Therapeutic\nStrategies"],"prefix":"10.2174","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0700-5878","authenticated-orcid":true,"given":"Ankita","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7599-5204","authenticated-orcid":true,"given":"Jitendra","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8135-1977","authenticated-orcid":true,"given":"Vijay","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","unstructured":"WHO. Key facts Hepatitis B. 2021. Available From:"},{"key":"ref=2","unstructured":"WHO. Global hepatitis report. 2017. Available From:"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1146\/annurev-med-080119-103356","volume":"72","author":"Naggie S.","year":"2021","unstructured":"Naggie S.; Lok A.S.; New Therapeutics for Hepatitis B: The Road to Cure. Annu Rev Med 2021,72(1),93-105","journal-title":"Annu Rev Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/hep.21513","volume":"45","author":"Lok A.S.F.","year":"2007","unstructured":"Lok A.S.F.; McMahon B.J.; Chronic hepatitis B. Hepatology 2007,45(2),507-539","journal-title":"Hepatology"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrgastro.2011.33","volume":"8","author":"Kwon H.","year":"2011","unstructured":"Kwon H.; Lok A.S.; Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011,8(5),275-284","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.20517\/2394-5079.2016.05","volume":"2","author":"Lamontagne R.J.","year":"2016","unstructured":"Lamontagne R.J.; Bagga S.; Bouchard M.J.; Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res 2016,2(7),163-186","journal-title":"Hepatoma Res"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","volume":"479-480","author":"Seeger C.","year":"2015","unstructured":"Seeger C.; Mason W.S.; Molecular biology of hepatitis B virus infection. Virology 2015,479-480,672-686","journal-title":"Virology"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/0092-8674(82)90157-X","volume":"29","author":"Summers J.","year":"1982","unstructured":"Summers J.; Mason W.S.; Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982,29(2),403-415","journal-title":"Cell"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1056\/NEJMra031087","volume":"350","author":"Ganem D.","year":"2004","unstructured":"Ganem D.; Prince A.M.; Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 2004,350(11),1118-1129","journal-title":"N Engl J Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"20160274","DOI":"10.1098\/rstb.2016.0274","volume":"372","author":"Ringehan M.","year":"2017","unstructured":"Ringehan M.; McKeating J.A.; Protzer U.;  Viral hepatitis and liver cancer Philos Trans R Soc Lond B Biol Sci 2017,372(1732),20160274","journal-title":"Viral hepatitis and liver cancer Philos Trans R Soc Lond B Biol Sci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.jhep.2016.02.011","volume":"64","author":"Li W.","year":"2016","unstructured":"Li W.; Urban S.; Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications. J Hepatol 2016,64(1)(Suppl.),S32-S40","journal-title":"J Hepatol"},{"key":"ref=12","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00049","volume":"1","author":"Yan H.","year":"2012","unstructured":"Yan H.; Zhong G.; Xu G.; He W.; Jing Z.; Gao Z.; Huang Y.; Qi Y.; Peng B.; Wang H.; Fu L.; Song M.; Chen P.; Gao W.; Ren B.; Sun Y.; Cai T.; Feng X.; Sui J.; Li W.; Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 2012,1","journal-title":"eLife"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.coviro.2013.12.002","volume":"4","author":"Baumert T.F.","year":"2014","unstructured":"Baumert T.F.; Meredith L.; Ni Y.; Felmlee D.J.; McKeating J.A.; Urban S.; Entry of hepatitis B and C viruses \u2014 recent progress and future impact. Curr Opin Virol 2014,4,58-65","journal-title":"Curr Opin Virol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.3390\/v13081463","volume":"13","author":"Wei L.","year":"2021","unstructured":"Wei L.; Ploss A.; Mechanism of Hepatitis B Virus cccDNA Formation. Viruses 2021,13(8),1463","journal-title":"Viruses"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jhep.2016.01.027","volume":"64","author":"Tong S.","year":"2016","unstructured":"Tong S.; Revill P.; Overview of hepatitis B viral replication and genetic variability. J Hepatol 2016,64(1)(Suppl.),S4-S16","journal-title":"J Hepatol"},{"key":"ref=16","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2015.01491","author":"Koumbi L.","year":"2016","unstructured":"Koumbi L.; Karayiannis P.;  The epigenetic control of hepatitis B virus modulates the outcome of infection Front Microbiol, 6, 1491 2016","journal-title":"The epigenetic control of hepatitis B virus modulates the outcome of infection Front Microbiol, 6, 1491"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/978-3-642-18932-6_12","volume":"166","author":"Kumar V.","year":"2004","unstructured":"Kumar V.; Sarkar D.P.; Hepatitis B.; Virus X protein (HBx): Structure-function relationships and role in viral pathogenesis. Handb Exp Pharmacol 2004,166,377-407","journal-title":"Handb Exp Pharmacol"},{"key":"ref=18","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021402","volume":"6","author":"Slagle B.L.","year":"2016","unstructured":"Slagle B.L.; Bouchard M.J.; Hepatitis B.; Hepatitis B virus X and regulation of viral gene expression. Cold Spring Harb Perspect Med 2016,6(3)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3390\/ijms17060940","volume":"17","author":"Liu S.","year":"2016","unstructured":"Liu S.; Koh S.; Lee C.; Hepatitis B.; Virus X.; Protein and Hepatocarcinogenesis. Int J Mol Sci 2016,17(6),940","journal-title":"Int J Mol Sci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1016\/j.celrep.2016.08.026","volume":"16","author":"Murphy C.M.","year":"2016","unstructured":"Murphy C.M.; Xu Y.; Li F.; Nio K.; Reszka-Blanco N.; Li X.; Wu Y.; Yu Y.; Xiong Y.; Su L.; Hepatitis B.; Virus X.; Hepatitis B Virus X protein promotes degradation of SMC5\/6 to enhance HBV replication. Cell Rep 2016,16(11),2846-2854","journal-title":"Cell Rep"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3389\/fmicb.2018.00662","volume":"9","author":"Mohebbi A.","year":"2018","unstructured":"Mohebbi A.; Lorestani N.; Tahamtan A.; Kargar N.L.; Tabarraei A.; An overview of Hepatitis B virus surface antigen secretion inhibitors. Front Microbiol 2018,9,662","journal-title":"Front Microbiol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"4565","DOI":"10.4049\/jimmunol.1501504","volume":"195","author":"Stavrou S.","year":"2015","unstructured":"Stavrou S.; Ross S.R.; APOBEC3 proteins in viral immunity. J Immunol 2015,195(10),4565-4570","journal-title":"J Immunol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3390\/biomedicines9111577","volume":"9","author":"Niklasch M.","year":"2021","unstructured":"Niklasch M.; Zimmermann P.; Nassal M.; The hepatitis B virus nucleocapsid-Dynamic compartment for infectious virus production and new antiviral target. Biomedicines 2021,9(11),1577","journal-title":"Biomedicines"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3390\/cells9092023","volume":"9","author":"Jiang B.","year":"2020","unstructured":"Jiang B.; Hildt E.; Intracellular trafficking of HBV particles. Cells 2020,9(9),2023","journal-title":"Cells"},{"key":"ref=25","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021394","volume":"5","author":"Selzer L.","year":"2015","unstructured":"Selzer L.; Zlotnick A.; Assembly and release of hepatitis B virus. Cold Spring Harb Perspect Med 2015,5(12)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.3389\/fimmu.2019.03127","volume":"10","author":"Meng Z.","year":"2020","unstructured":"Meng Z.; Chen Y.; Lu M.; Advances in targeting the innate and adaptive immune systems to cure chronic hepatitis B virus infection. Front Immunol 2020,10,3127","journal-title":"Front Immunol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3748\/wjg.v22.i1.145","volume":"22","author":"Caligiuri P.","year":"2016","unstructured":"Caligiuri P.; Cerruti R.; Icardi G.; Bruzzone B.; Overview of hepatitis B virus mutations and their implications in the management of infection. World J Gastroenterol 2016,22(1),145-154","journal-title":"World J Gastroenterol"},{"key":"ref=28","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021493","volume":"5","author":"Chang M.H.","year":"2015","unstructured":"Chang M.H.; Chen D.S.; Prevention of hepatitis B. Cold Spring Harb Perspect Med 2015,5(3)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"8495","DOI":"10.1073\/pnas.88.19.8495","volume":"88","author":"Doong S.L.","year":"1991","unstructured":"Doong S.L.; Tsai C.H.; Schinazi R.F.; Liotta D.C.; Cheng Y.C.; Inhibition of the replication of hepatitis B virus in vitroby 2\u20323\u2032-dideoxy-3\u2032-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991,88(19),8495-8499","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJM199512213332501","volume":"333","author":"Dienstag J.L.","year":"1995","unstructured":"Dienstag J.L.; Perrillo R.P.; Schiff E.R.; Bartholomew M.; Vicary C.; Rubin M.; A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995,333(25),1657-1661","journal-title":"N Engl J Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2165\/00044011-200727010-00003","volume":"27","author":"Dienstag J.L.","year":"2007","unstructured":"Dienstag J.L.; Wei L.J.; Xu D.; Kreter B.; Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. Clin Drug Investig 2007,27(1),35-49","journal-title":"Clin Drug Investig"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/hep.510290321","volume":"29","author":"Tassopoulos N.C.","year":"1999","unstructured":"Tassopoulos N.C.; Volpes R.; Pastore G.; Heathcote J.; Buti M.; Goldin R.D.; Hawley S.; Barber J.; Condreay L.; Gray D.F.; Efficacy of lamivudine in patients with hepatitis B e antigen-negative\/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen-negative\/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen-negative\/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen-negative\/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis BB. Hepatology Lamivudine Precore Mutant Study Group1999,29(3),889-896","journal-title":"Hepatology"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/jhep.2002.34740","volume":"36","author":"Yang H.","year":"2002","unstructured":"Yang H.; Westland C.E.; Delaney W.E.; Heathcote E.J.; Ho V.; Fry J.; Brosgart C.; Gibbs C.S.; Miller M.D.; Xiong S.; Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002,36(2),464-473","journal-title":"Hepatology"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","volume":"125","author":"Lok A.S.F.","year":"2003","unstructured":"Lok A.S.F.; Lai C.L.; Leung N.; Yao G.B.; Cui Z.Y.; Schiff E.R.; Dienstag J.L.; Heathcote E.J.; Little N.R.; Griffiths D.A.; Gardner S.D.; Castiglia M.; Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003,125(6),1714-1722","journal-title":"Gastroenterology"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/hep.510290340","volume":"29","author":"Ono-Nita S.K.","year":"1999","unstructured":"Ono-Nita S.K.; Kato N.; Shiratori Y.; Masaki T.; Lan K.H.; Carrilho F.J.; Omata M.; YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study byin vitrofull-length viral DNA transfection. Hepatology 1999,29(3),939-945","journal-title":"Hepatology"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/3435965","volume":"2016","author":"Wang H-L.","year":"2016","unstructured":"Wang H-L.; Lu X.; Yang X.; Xu N.; Antiviraxients: A systematic review and network meta-analysis. Gastroenterol Res Pract 2016,2016,1-10","journal-title":"Gastroenterol Res Pract"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1, CMT.S2321","DOI":"10.4137\/CMT.S2321","author":"Charuworn P.","year":"2009","unstructured":"Charuworn P.; Keeffe E.B.; A review of the use of telbivudine in the treatment of chronic hepatitis B. B Clin Med Ther 2009,1, CMT.S2321","journal-title":"B Clin Med Ther"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.2165\/00003495-200767130-00011","volume":"67","author":"Keam S.J.","year":"2007","unstructured":"Keam S.J.; Telbivudine. Drugs 2007,67(13),1917-1929","journal-title":"Drugs"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","volume":"135","author":"Buster E.H.C.J.","year":"2008","unstructured":"Buster E.H.C.J.; Flink H.J.; Cakaloglu Y.; Simon K.; Trojan J.; Tabak F.; So T.M.K.; Feinman S.V.; Mach T.; Akarca U.S.; Schutten M.; Tielemans W.; van Vuuren A.J.; Hansen B.E.; Janssen H.L.A.; Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008,135(2),459-467","journal-title":"Gastroenterology"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1128\/AAC.41.7.1444","volume":"41","author":"Innaimo S.F.","year":"1997","unstructured":"Innaimo S.F.; Seifer M.; Bisacchi G.S.; Standring D.N.; Zahler R.; Colonno R.J.; Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997,41(7),1444-1448","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2165\/00003495-200969080-00005","volume":"69","author":"Scott L.J.","year":"2009","unstructured":"Scott L.J.; Keating G.M.; Entecavir. Drugs 2009,69(8),1003-1033","journal-title":"Drugs"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1517\/13543780802535760","volume":"17","author":"Asselah T.","year":"2008","unstructured":"Asselah T.; Lada O.; Moucari R.; Marcellin P.; Clevudine: A promising therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2008,17(12),1963-1974","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1365-2893.2010.01281.x","volume":"18","author":"Jang J.H.","year":"2011","unstructured":"Jang J.H.; Kim J.W.; Jeong S.H.; Myung H.J.; Kim H.S.; Park Y.S.; Lee S.H.; Hwang J.H.; Kim N.; Lee D.H.; Clevudine for chronic hepatitis B: Antiviral response, predictors of response, and development of myopathy. J Viral Hepat 2011,18(2),84-90","journal-title":"J Viral Hepat"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.2165\/00003495-200363200-00007","volume":"63","author":"Dando T.M.","year":"2003","unstructured":"Dando T.M.; Plosker G.L.; Adefovir Dipivoxil. Drugs 2003,63(20),2215-2234","journal-title":"Drugs"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","volume":"131","author":"Hadziyannis S.J.","year":"2006","unstructured":"Hadziyannis S.J.; Tassopoulos N.C.; Heathcote E.J.; Chang T.T.; Kitis G.; Rizzetto M.; Marcellin P.; Lim S.G.; Goodman Z.; Ma J.; Brosgart C.L.; Borroto-Esoda K.; Arterburn S.; Chuck S.L.; Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology Adefovir Dipivoxil 438 Study Group2006,131(6),1743-1751","journal-title":"Gastroenterology"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nrd1877","volume":"4","author":"Clercq E.D.","year":"2005","unstructured":"Clercq E.D.; Hol\u00fd A.; Acyclic nucleoside phosphonates: A key class of antiviral drugs. Nat Rev Drug Discov 2005,4(11),928-940","journal-title":"Nat Rev Drug Discov"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1128\/AAC.37.2.332","volume":"37","author":"Balzarini J.","year":"1993","unstructured":"Balzarini J.; Holy A.; Jindrich J.; Naesens L.; Snoeck R.; Schols D.; De Clercq E.; Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitroand in vivoantiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother 1993,37(2),332-338","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.2165\/10482940-000000000-00000","volume":"69","author":"Perry C.M.","year":"2009","unstructured":"Perry C.M.; Simpson D.; Tenofovir disoproxil fumarate: In chronic hepatitis B. Drugs 2009,69(16),2245-2256","journal-title":"Drugs"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00535-020-01698-4","volume":"55","author":"Charlton M.R.","year":"2020","unstructured":"Charlton M.R.; Alam A.; Shukla A.; Dashtseren B.; Lesmana C.R.A.; Duger D.; Payawal D.A.; Duy Cuong D.; Jargalsaikhan G.; Cua I.H.Y.; Sollano J.D.; Singh K.R.; Madan K.; Win K.M.; Kyi K.P.; Tun K.S.; Salih M.; Rastogi M.; Saraf N.; Thuy P.T.T.; Hien P.T.D.; Gani R.A.; Mohamed R.; Tanwandee T.; Piratvisuth T.; Sukeepaisarnjaroen W.; Naing W.; Hashmi Z.Y.; An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J Gastroenterol 2020,55(9),811-823","journal-title":"J Gastroenterol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cytogfr.2014.07.015","volume":"25","author":"Lin F.","year":"2014","unstructured":"Lin F.; Young H.A.; Interferons: Success in anti-viral immunotherapy. Cytokine Growth Factor Rev 2014,25(4),369-376","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000360941","volume":"57","author":"Brunetto M.R.","year":"2014","unstructured":"Brunetto M.R.; Bonino F.; Interferon therapy of chronic hepatitis B. Intervirology 2014,57(3-4),163-170","journal-title":"Intervirology"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s40121-017-0173-y","volume":"6","author":"Arends J.E.","year":"2017","unstructured":"Arends J.E.; Lieveld F.I.; Ahmad S.; Ustianowski A.; New viral and immunological targets for hepatitis B treatment and cure: A review. Infect Dis Ther 2017,6(4),461-476","journal-title":"Infect Dis Ther"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1128\/AAC.00460-07","volume":"51","author":"Painter G.R.","year":"2007","unstructured":"Painter G.R.; Almond M.R.; Trost L.C.; Lampert B.M.; Neyts J.; De Clercq E.; Korba B.E.; Aldern K.A.; Beadle J.R.; Hostetler K.Y.; Evaluation of hexadecyloxypropyl-9-R-[2-(Phosphonomethoxy)propyl]- adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections. Antimicrob Agents Chemother 2007,51(10),3505-3509","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/gutjnl-2013-305138","volume":"63","author":"Lai C.L.","year":"2014","unstructured":"Lai C.L.; Ahn S.H.; Lee K.S.; Um S.H.; Cho M.; Yoon S.K.; Lee J.W.; Park N.H.; Kweon Y.O.; Sohn J.H.; Lee J.; Kim J.A.; Han K.H.; Yuen M.F.; Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut 2014,63(6),996-1004","journal-title":"Gut"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejmech.2015.06.030","author":"Lv Z.","year":"2015","unstructured":"Lv Z.; He W.; Tian W.; Kang J.; Liu Y.; Peng Y.; Zheng L.; Wang Q.; Yu W.; Chang J.; Design, synthesis, and biological evaluation of new N4-Substituted 2\u2032-deoxy-2\u2032-fluoro-4\u2032-azido cytidine derivatives as potent anti-HBV agents. Eur J Med Chem 2015,101-, 103-110","journal-title":"Eur J Med Chem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.bmc.2016.12.017","volume":"25","author":"Ren Q.","year":"2017","unstructured":"Ren Q.; Liu X.; Luo Z.; Li J.; Wang C.; Goldmann S.; Zhang J.; Zhang Y.; Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4). Bioorg Med Chem 2017,25(3),1042-1056","journal-title":"Bioorg Med Chem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"6066","DOI":"10.1021\/acs.jmedchem.0c00292","volume":"63","author":"Wang C.","year":"2020","unstructured":"Wang C.; Pei Y.; Wang L.; Li S.; Jiang C.; Tan X.; Dong Y.; Xiang Y.; Ma Y.; Liu G.; Discovery of (1 H -Pyrazolo[3,4-c]pyridin-5-yl)sulfonamide analogues as hepatitis B virus capsid assembly modulators by conformation constraint. J Med Chem 2020,63(11),6066-6089","journal-title":"J Med Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1053\/j.gastro.2018.12.023","volume":"156","author":"Yuen M.F.","year":"2019","unstructured":"Yuen M.F.; Gane E.J.; Kim D.J.; Weilert F.; Yuen Chan; H.L.; Lalezari, J.; Hwang, S.G.; Nguyen, T.; Flores, O.; Hartman, G.; Liaw, S.; Lenz, O.; Kakuda, T.N.; Talloen, W.; Schwabe, C.; Klumpp, K.; Brown, N. Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection. Gastroenterology 2019,156(5),1392-1403.e7","journal-title":"Gastroenterology"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"931A","DOI":"10.1002\/hep.28800","volume":"64","author":"Kakuda T.","year":"2016","unstructured":"Kakuda T.; Bene F.D.; Yuen M-F.; Gone E.J.; Kim S.; Liaw S.; Brown N.; Klumpp K.; Flores L.; Chanda S.; Pharmacokinetics (PK) and PK modeling of the first-in- class HBV core inhibitor NVR 3-778 dosed once- (QD) or twice daily (BD) in healthy volunteers (HVs) and HBeAg-positive patients with chronic HBV infection (CHBV). Hepatology 2016,64,931A","journal-title":"Hepatology"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"e01463","DOI":"10.1128\/AAC.01463-20","volume":"64","author":"Huang Q.","year":"2020","unstructured":"Huang Q.; Cai D.; Yan R.; Li L.; Zong Y.; Guo L.; Mercier A.; Zhou Y.; Tang A.; Henne K.; Colonno R.; Preclinical profile and characterization of the hepatitis b virus core protein inhibitor abi-h0731. Antimicrob Agents Chemother 2020,64(11),e01463-e20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S2468-1253(19)30346-2","volume":"5","author":"Yuen M.F.","year":"2020","unstructured":"Yuen M.F.; Agarwal K.; Gane E.J.; Schwabe C.; Ahn S.H.; Kim D.J.; Lim Y.S.; Cheng W.; Sievert W.; Visvanathan K.; Ruby E.; Liaw S.; Yan R.; Huang Q.; Colonno R.; Lopatin U.; Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: A randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol Hepatol 2020,5(2),152-166","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S0618-8278(19)30936-3","volume":"70","author":"Vaine M.","year":"2019","unstructured":"Vaine M.; Dellisola V.; Clugston S.; Cao H.; Gao X.; Kass J.; Li W.; Peng X.; Qiu Y.L.; Jiang L.; Daniels K.; Or Y.S.; Goodwin B.; Lin K.; FRI-191-EDP-514, a novel HBV core inhibitor with potent antiviral activity both in vitro and in vivo. J Hepatol 2019,70(1),e474-e475","journal-title":"J Hepatol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","volume":"159","author":"Zoulim F.","year":"2020","unstructured":"Zoulim F.; Lenz O.; Vandenbossche J.J.; Talloen W.; Verbinnen T.; Moscalu I.; Streinu-Cercel A.; Bourgeois S.; Buti M.; Crespo J.; Manuel Pascasio J.; Sarrazin C.; Vanwolleghem T.; Shukla U.; Fry J.; Yogaratnam J.Z.; JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection. Gastroenterology 2020,159(2),521-533.e9","journal-title":"Gastroenterology"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"e02439","DOI":"10.1128\/AAC.02439-19","volume":"64","author":"Berke J.M.","year":"2020","unstructured":"Berke J.M.; Dehertogh P.; Vergauwen K.; Mostmans W.; Vandyck K.; Raboisson P.; Pauwels F.; Antiviral properties and mechanism of action studies of the hepatitis b virus capsid assembly modulator JNJ-56136379. Antimicrob Agents Chemother 2020,64(5),e02439-e19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=65","first-page":"239A","volume":"2018","author":"Berke J.M.","year":"2018","unstructured":"Berke J.M.; Dehertogh P.; Vergauwen K.; Verbinnen T.; Vendeville S.; Raboisson P.; Pauwels F.; In vitro antiviral activity and mode of action of JNJ-64530440, a novel potent hepatitis B virus capsid assembly modulator in clinical development. Hepatology 2018,2018(68)(Suppl. 1),239A","journal-title":"Hepatology"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/13596535211044331","volume":"26","author":"Kakuda T.N.","year":"2021","unstructured":"Kakuda T.N.; Yogaratnam J.Z.; Westland C.; Gane E.J.; Schwabe C.; Vuong J.; Patel M.; Snoeys J.; Talloen W.; Lenz O.; Fry J.; Chanda S.; van Remoortere P.; Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers. Antivir Ther 2021,26(1-2),13-24","journal-title":"Antivir Ther"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/jac\/dkab491","volume":"77","author":"Gane E.J.","year":"2022","unstructured":"Gane E.J.; Schwabe C.; Berliba E.; Tangkijvanich P.; Jucov A.; Ghicavii N.; Verbinnen T.; Lenz O.; Talloen W.; Kakuda T.N.; Westland C.; Patel M.; Yogaratnam J.Z.; Dragone L.; Van Remoortere P.; Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection. J Antimicrob Chemother 2022,77(4),1102-1110","journal-title":"J Antimicrob Chemother"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/cpt.2184","volume":"109","author":"Cosson V.","year":"2021","unstructured":"Cosson V.; Feng S.; Jaminion F.; Lemenuel-Diot A.; Parrott N.; Paehler A.; Bo Q.; Jin Y.; How Semiphysiological Population Pharmacokinetic Modeling Incorporating active hepatic uptake supports phase ii dose selection of ro7049389, a novel anti\u2013hepatitis B virus drug. Clin Pharmacol Ther 2021,109(4),1081-1091","journal-title":"Clin Pharmacol Ther"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S2468-1253(21)00176-X","volume":"6","author":"Yuen M.F.","year":"2021","unstructured":"Yuen M.F.; Zhou X.; Gane E.; Schwabe C.; Tanwandee T.; Feng S.; Jin Y.; Triyatni M.; Lemenuel-Diot A.; Cosson V.; Xue Z.; Kazma R.; Bo Q.; Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: A multicentre, randomised, placebo-controlled, phase 1 trial. Lancet Gastroenterol Hepatol 2021,6(9),723-732","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1053\/j.gastro.2018.07.057","volume":"156","author":"Xia Y.","year":"2019","unstructured":"Xia Y.; Liang T.J.; Development of direct-acting antiviral and host-targeting agents for treatment of hepatitis B virus infection. Gastroenterology 2019,156(2),311-324","journal-title":"Gastroenterology"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"e01686","DOI":"10.1128\/AAC.01686-19","volume":"64","author":"Zhao N.","year":"2019","unstructured":"Zhao N.; Jia B.; Zhao H.; Xu J.; Sheng X.; Luo L.; Huang Z.; Wang X.; Ren Q.; Zhang Y.; Zhao X.; Cui Y.; A first-in-human trial of GLS4, a novel inhibitor of hepatitis b virus capsid assembly, following single- and multiple-ascending-oral-dose studies with or without ritonavir in healthy adult volunteers. Antimicrob Agents Chemother 2019,64(1),e01686-e19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/cid\/ciaa961","volume":"73","author":"Zhang H.","year":"2021","unstructured":"Zhang H.; Wang F.; Zhu X.; Chen Y.; Chen H.; Li X.; Wu M.; Li C.; Liu J.; Zhang Y.; Ding Y.; Niu J.; Antiviral activity and pharmacokinetics of the hepatitis B Virus (HBV) capsid assembly modulator GLS4 in patients with chronic HBV infection. Clin Infect Dis 2021,73(2),175-182","journal-title":"Clin Infect Dis"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/aps.2013.175","volume":"35","author":"Yang L.","year":"2014","unstructured":"Yang L.; Shi L.; Chen H.; Tong X.K.; Wang G.; Zhang Y.; Wang W.; Feng C.; He P.; Zhu F.; Hao Y.; Wang B.; Yang D.; Tang W.; Nan F.; Zuo J.; Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation. Acta Pharmacol Sin 2014,35(3),410-418","journal-title":"Acta Pharmacol Sin"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"7061","DOI":"10.1128\/AAC.01558-15","volume":"59","author":"Wang Y.J.","year":"2015","unstructured":"Wang Y.J.; Lu D.; Xu Y.B.; Xing W.Q.; Tong X.K.; Wang G.F.; Feng C.L.; He P.L.; Yang L.; Tang W.; Hu Y.H.; Zuo J.P.; A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation. Antimicrob Agents Chemother 2015,59(11),7061-7072","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1038\/s41467-019-10200-5","volume":"10","author":"Kang J.A.","year":"2019","unstructured":"Kang J.A.; Kim S.; Park M.; Park H.J.; Kim J.H.; Park S.; Hwang J.R.; Kim Y.C.; Jun Kim Y.; Cho Y.; Sun Jin; M.; Park, S.G. Ciclopirox inhibits Hepatitis B Virus secretion by blocking capsid assembly. Nat Commun 2019,10(1),2184","journal-title":"Nat Commun"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"11945","DOI":"10.1128\/JVI.01855-15","volume":"89","author":"Kaneko M.","year":"2015","unstructured":"Kaneko M.; Watashi K.; Kamisuki S.; Matsunaga H.; Iwamoto M.; Kawai F.; Ohashi H.; Tsukuda S.; Shimura S.; Suzuki R.; Aizaki H.; Sugiyama M.; Park S.Y.; Ito T.; Ohtani N.; Sugawara F.; Tanaka Y.; Mizokami M.; Sureau C.; Wakita T.; A novel tricyclic polyketide, vanitaracin a, specifically inhibits the entry of hepatitis b and d viruses by targeting sodium taurocholate cotransporting polypeptide. J Virol 2015,89(23),11945-11953","journal-title":"J Virol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jhep.2013.11.022","volume":"60","author":"Nkongolo S.","year":"2014","unstructured":"Nkongolo S.; Ni Y.; Lempp F.A.; Kaufman C.; Lindner T.; Esser-Nobis K.; Lohmann V.; Mier W.; Mehrle S.; Urban S.; Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol 2014,60(4),723-731","journal-title":"J Hepatol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1002\/hep.26982","volume":"59","author":"Watashi K.","year":"2014","unstructured":"Watashi K.; Sluder A.; Daito T.; Matsunaga S.; Ryo A.; Nagamori S.; Iwamoto M.; Nakajima S.; Tsukuda S.; Borroto-Esoda K.; Sugiyama M.; Tanaka Y.; Kanai Y.; Kusuhara H.; Mizokami M.; Wakita T.; Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology 2014,59(5),1726-1737","journal-title":"Hepatology"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.antiviral.2015.06.007","volume":"120","author":"Wang X.","year":"2015","unstructured":"Wang X.; Hu W.; Zhang T.; Mao Y.; Liu N.; Wang S.; Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na+-dependent taurocholate cotransporting polypeptide activity. Antiviral Res 2015,120,140-146","journal-title":"Antiviral Res"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.antiviral.2012.12.008","volume":"97","author":"Lucifora J.","year":"2013","unstructured":"Lucifora J.; Esser K.; Protzer U.; Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes. Antiviral Res 2013,97(2),195-197","journal-title":"Antiviral Res"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1002\/hep.28952","volume":"65","author":"Tsukuda S.","year":"2017","unstructured":"Tsukuda S.; Watashi K.; Hojima T.; Isogawa M.; Iwamoto M.; Omagari K.; Suzuki R.; Aizaki H.; Kojima S.; Sugiyama M.; Saito A.; Tanaka Y.; Mizokami M.; Sureau C.; Wakita T.; A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins. Hepatology 2017,65(4),1104-1116","journal-title":"Hepatology"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jhep.2012.12.008","volume":"58","author":"Volz T.","year":"2013","unstructured":"Volz T.; Allweiss, L.; \u1e3eBarek, M.B.; Warlich, M.; Lohse, A.W.; Pollok, J.M.; Alexandrov, A.; Urban, S.; Petersen, J.; L\u00fctgehetmann, M.; Dandri, M. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 2013,58(5),861-867","journal-title":"J Hepatol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","volume":"147","author":"Urban S.","year":"2014","unstructured":"Urban S.; Bartenschlager R.; Kubitz R.; Zoulim F.; Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 2014,147(1),48-64","journal-title":"Gastroenterology"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","volume":"65","author":"Bogomolov P.","year":"2016","unstructured":"Bogomolov P.; Alexandrov A.; Voronkova N.; Macievich M.; Kokina K.; Petrachenkova M.; Lehr T.; Lempp F.A.; Wedemeyer H.; Haag M.; Schwab M.; Haefeli W.E.; Blank A.; Urban S.; Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib\/IIa study. J Hepatol 2016,65(3),490-498","journal-title":"J Hepatol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.antiviral.2013.06.007","volume":"99","author":"Hu Y.","year":"2013","unstructured":"Hu Y.; Cheng, X.; Cao, F.; Huang, A.; Tavis, J.E. \u03b2-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity. Antiviral Res 2013,99(3),221-229","journal-title":"Antiviral Res"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1021\/acsinfecdis.8b00045","volume":"5","author":"Tavis J.E.","year":"2019","unstructured":"Tavis J.E.; Zoidis G.; Meyers M.J.; Murelli R.P.; Chemical Approaches to Inhibiting the Hepatitis B Virus Ribonuclease H. ACS Infect Dis 2019,5(5),655-658","journal-title":"ACS Infect Dis"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"12577","DOI":"10.1074\/jbc.M117.775155","volume":"292","author":"Ghosh S.","year":"2017","unstructured":"Ghosh S.; Kaushik A.; Khurana S.; Varshney A.; Singh A.K.; Dahiya P.; Thakur J.K.; Sarin S.K.; Gupta D.; Malhotra P.; Mukherjee S.K.; Bhatnagar R.K.; An RNAi-based high-throughput screening assay to identify small molecule inhibitors of hepatitis B virus replication. J Biol Chem 2017,292(30),12577-12588","journal-title":"J Biol Chem"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jcmgh.2018.10.010","volume":"7","author":"Sekiba K.","year":"2019","unstructured":"Sekiba K.; Otsuka M.; Ohno M.; Yamagami M.; Kishikawa T.; Suzuki T.; Ishibashi R.; Seimiya T.; Tanaka E.; Koike K.; Inhibition of HBV Transcription From cccDNA With Nitazoxanide by Targeting the HBx\u2013DDB1 Interaction. Cell Mol Gastroenterol Hepatol 2019,7(2),297-312","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref=89","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2020.e03217","volume":"6","author":"Mishra S.","year":"2020","unstructured":"Mishra S.; Pandey A.; Manvati S.; Coumarin: An emerging antiviral agent. Heliyon 2020,6(1)","journal-title":"Heliyon"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.jhep.2020.09.019","volume":"74","author":"Cheng S.T.","year":"2021","unstructured":"Cheng S.T.; Hu J.L.; Ren J.H.; Yu H.B.; Zhong S.; Wai Wong V.K.; Kwan Law B.Y.; Chen W.X.; Xu H.M.; Zhang Z.Z.; Cai X.F.; Hu Y.; Zhang W.L.; Long Q.X.; Ren F.; Zhou H.Z.; Huang A.L.; Chen J.; Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx. J Hepatol 2021,74(3),522-534","journal-title":"J Hepatol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2017.04.019","volume":"8","author":"Roehl I.","year":"2017","unstructured":"Roehl I.; Seiffert S.; Brikh C.; Quinet J.; Jamard C.; Dorfler N.; Lockridge J.A.; Cova L.; Vaillant A.; Nucleic acid polymers with accelerated plasma and tissue clearance for chronic hepatitis B therapy. Mol Ther Nucleic Acids 2017,8,1-12","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1002\/hep.29737","volume":"67","author":"Quinet J.","year":"2018","unstructured":"Quinet J.; Jamard C.; Burtin M.; Lemasson M.; Guerret S.; Sureau C.; Vaillant A.; Cova L.; Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks. Hepatology 2018,67(6),2127-2140","journal-title":"Hepatology"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","volume":"158","author":"Bazinet M.","year":"2020","unstructured":"Bazinet M.; P\u00e2ntea V.; Placinta G.; Moscalu I.; Cebotarescu V.; Cojuhari L.; Jimbei P.; Iarovoi L.; Smesnoi V.; Musteata T.; Jucov A.; Dittmer U.; Krawczyk A.; Vaillant A.; Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection na\u00efve to nucleos(t)ide therapy. Gastroenterology 2020,158(8),2180-2194","journal-title":"Gastroenterology"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/hep4.1633","volume":"5","author":"Bazinet M.","year":"2021","unstructured":"Bazinet M.; P\u00e2ntea V.; Cebotarescu V.; Cojuhari L.; Jimbei P.; Anderson M.; Gersch J.; Holzmayer V.; Elsner C.; Krawczyk A.; Kuhns M.C.; Cloherty G.; Dittmer U.; Vaillant A.; Persistent control of hepatitis B virus and hepatitis delta virus infection following rep 2139-ca and pegylated interferon therapy in chronic hepatitis b virus\/hepatitis delta virus coinfection. Hepatol Commun 2021,5(2),189-202","journal-title":"Hepatol Commun"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"5660","DOI":"10.1021\/jm200696v","volume":"54","author":"Yu W.","year":"2011","unstructured":"Yu W.; Goddard C.; Clearfield E.; Mills C.; Xiao T.; Guo H.; Morrey J.D.; Motter N.E.; Zhao K.; Block T.M.; Cuconati A.; Xu X.; Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion. J Med Chem 2011,54(16),5660-5670","journal-title":"J Med Chem"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.antiviral.2014.04.002","volume":"107","author":"Xu Y.B.","year":"2014","unstructured":"Xu Y.B.; Yang L.; Wang G.F.; Tong X.K.; Wang Y.J.; Yu Y.; Jing J.F.; Feng C.L.; He P.L.; Lu W.; Tang W.; Zuo J.P.; Benzimidazole derivative, BM601, a novel inhibitor of hepatitis B virus and HBsAg secretion. Antiviral Res 2014,107,6-15","journal-title":"Antiviral Res"},{"key":"ref=97","author":"Han X.","year":"2015","unstructured":"Han X.; Javanbakht H.; Jiang M.; Liang C.; Wang J.; Wang Y.; Wang Z.; Weikert R.J.; Yang S.; Zhou C.; US9458153, 2015"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"S693","DOI":"10.1016\/S0168-8278(17)31861-5","volume":"66","author":"Wildum S.","year":"2017","unstructured":"Wildum S.; Steiner G.; Luangsay S.; Suresh M.; Korolowicz K.; Balarezo M.; Yon C.; Murreddu M.; Hong X.; Kallakury B.; Tucker R.; Mueller H.; Menne S.; Young J.; Javanbakht H.; Antiviral efficacy of a novel hepatitis B virus expression inhibitor in combination with entecavir and wIFN-alpha in woodchucks model of chronic hepatitis B. J Hepatol 2017,66(1),S693","journal-title":"J Hepatol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1016\/j.cgh.2019.09.038","volume":"18","author":"Lee H.W.","year":"2020","unstructured":"Lee H.W.; Park J.Y.; Hong T.; Park M.S.; Ahn S.H.; Efficacy of lenvervimab, a recombinant human immunoglobulin, in treatment of chronic hepatitis B virus infection. Clin Gastroenterol Hepatol 2020,18(13),3043-3045.e1","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=100","author":"Guo J.","year":"2018","unstructured":"Guo J.; Chang J.; Block T.M.; Kinney W.A.; Almond H.R.; Almond, modulation of hepatitis B virus cccDNA transcription. US10143720B2, 2018"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"8526","DOI":"10.1073\/pnas.0609883104","volume":"104","author":"Ying C.","year":"2007","unstructured":"Ying C.; Li Y.; Leung C.H.; Robek M.D.; Cheng Y.C.; Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. Proc Natl Acad Sci USA 2007,104(20),8526-8531","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.bmc.2009.12.038","volume":"18","author":"Janmanchi D.","year":"2010","unstructured":"Janmanchi D.; Tseng Y.P.; Wang K.C.; Huang R.L.; Lin C.H.; Yeh S.F.; Synthesis and the biological evaluation of arylnaphthalene lignans as anti-hepatitis B virus agents. Bioorg Med Chem 2010,18(3),1213-1226","journal-title":"Bioorg Med Chem"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3851\/IMP1686","volume":"21","author":"Ying C.","year":"2010","unstructured":"Ying C.; Tan S.; Cheng Y.C.; Helioxanthin analogue 8-1 inhibits duck hepatitis B virus replication in cell culture. Antivir Chem Chemother 2010,21(2),97-103","journal-title":"Antivir Chem Chemother"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ejmech.2012.05.012","volume":"54","author":"Wang L.J.","year":"2012","unstructured":"Wang L.J.; Geng C.A.; Ma Y.B.; Luo J.; Huang X.Y.; Chen H.; Zhou N.J.; Zhang X.M.; Chen J.J.; Design, synthesis, and molecular hybrids of caudatin and cinnamic acids as novel anti-hepatitis B virus agents. Eur J Med Chem 2012,54,352-365","journal-title":"Eur J Med Chem"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.antiviral.2013.09.007","volume":"100","author":"Huang Q.","year":"2013","unstructured":"Huang Q.; Huang R.; Wei L.; Chen Y.; Lv S.; Liang C.; Zhang X.; Yin F.; Li H.; Zhuo L.; Lin X.; Antiviral activity of methyl helicterate isolated from Helicteres angustifolia (Sterculiaceae) against hepatitis B virus. Antiviral Res 2013,100(2),373-381","journal-title":"Antiviral Res"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jep.2013.09.009","volume":"150","author":"Huang Q.","year":"2013","unstructured":"Huang Q.; Zhang S.; Huang R.; Wei L.; Chen Y.; Lv S.; Liang C.; Tan S.; liang, S.; Zhuo, L.; Lin, X. Isolation and identification of an anti-hepatitis B virus compound from Hydrocotyle sibthorpioides Lam. J Ethnopharmacol 2013,150(2),568-575","journal-title":"J Ethnopharmacol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1155\/2012\/356806","volume":"356806","author":"Wu Y-H.","year":"2012","unstructured":"Wu Y-H.; Hao B-J.; Cao H-C.; Xu W.; Li Y-J.; Li L-J.; Anti-hepatitis B virus effect and possible mechanism of action of 3,4-o-dicaffeoylquinic Acid in vitro and in vivo. Evid Based Complement Alternat Med 2012,356806,2012","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=108","author":"Vandyck K.","year":"2021","unstructured":"Vandyck K.; Rudolf B.; Chopped G.Y.P.; Last S.J.; Rombouts G.; McGowan D.C.; Verschueren G.R.; Raboisson P.J.B.; Sulfamoylpyrrolamide derivatives and their use as medicaments for the treatment of hepatitis b. WO2014184350A1, 2021"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"97-107.2016","DOI":"10.1016\/j.antiviral.2016.08.026","volume":"134","author":"Liu C.","year":"2016","unstructured":"Liu C.; Cai D.; Zhang L.; Tang W.; Yan R.; Guo H.; Chen X.; Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA. Antiviral Res 2016,134(2016),97-107.2016","journal-title":"Antiviral Res"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.antiviral.2007.04.004","volume":"76","author":"Lazar C.","year":"2007","unstructured":"Lazar C.; Durantel D.; Macovei A.; Zitzmann N.; Zoulim F.; Dwek R.; Branzanichita N.; Treatment of hepatitis B virus-infected cells with \u03b1-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity. Antiviral Res 2007,76(1),30-37","journal-title":"Antiviral Res"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41598-019-56842-9","volume":"10","author":"Hayakawa M.","year":"2020","unstructured":"Hayakawa M.; Umeyama H.; Iwadate M.; Taguchi Y.H.; Yano Y.; Honda T.; Itami-Matsumoto S.; Kozuka R.; Enomoto M.; Tamori A.; Kawada N.; Murakami Y.; Development of a novel anti-hepatitis B virus agent viaSp1. Sci Rep 2020,10(1),47","journal-title":"Sci Rep"},{"key":"ref=112","doi-asserted-by":"publisher","DOI":"10.3390\/v13061169","author":"Mak L.Y.","year":"2021","unstructured":"Mak L.Y.; Seto W.K.; Yuen M.F.;  Novel antivirals in clinical development for chronic hepatitis B infection Viruses 13(2021), 1169 2021","journal-title":"Novel antivirals in clinical development for chronic hepatitis B infection Viruses 13(2021), 1169"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/S0168-8278(20)30597-3","volume":"73","author":"Gane E.","year":"2020","unstructured":"Gane E.; Locarini S.; Lim T.H.; Strasser S.; Sievert W.; Cheng W.; Thompson A.; Given B.; Hamilton M.; Biermer R.; Kalmeijer R.; Beumont-Mauviel M.; Lenz O.; Cloherty G.; Wong D.K.H.; Schwabe C.; Jackson K.; Ferrari C.L.; Gish R.G.; Yuen M.F.; Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment. J Hepatol 2020,73,S10","journal-title":"J Hepatol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3350\/cmh.2021.0093","volume":"28","author":"Kim S.W.","year":"2022","unstructured":"Kim S.W.; Yoon J.S.; Lee M.; Cho Y.; Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus. Clin Mol Hepatol 2022,28(1),17-30","journal-title":"Clin Mol Hepatol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.3390\/cancers14061588","volume":"14","author":"Smith E.S.","year":"2022","unstructured":"Smith E.S.; Whitty E.; Yoo B.; Moore A.; Sempere L.F.; Medarova Z.; Clinical applications of short non-coding rna-based therapies in the era of precision medicine. Cancers 2022,14(6),1588","journal-title":"Cancers"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s40268-021-00369-w","volume":"21","author":"Gupta S.V.","year":"2021","unstructured":"Gupta S.V.; Fanget M.C.; MacLauchlin C.; Clausen V.A.; Li J.; Cloutier D.; Shen L.; Robbie G.J.; Mogalian E.; Clinical and preclinical single-dose pharmacokinetics of VIR-2218, an RNAi therapeutic targeting HBV infection. Drugs R D 2021,21(4),455-465","journal-title":"Drugs R D"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jhep.2022.05.031","volume":"77","author":"Yuen M.F.","year":"2022","unstructured":"Yuen M.F.; Heo J.; Kumada H.; Suzuki F.; Suzuki Y.; Xie Q.; Jia J.; Karino Y.; Hou J.; Chayama K.; Imamura M.; Lao-Tan J.Y.; Lim S.G.; Tanaka Y.; Xie W.; Yoon J.H.; Duan Z.; Kurosaki M.; Park S.J.; Labio M.E.; Kumar R.; Kweon Y.O.; Yim H.J.; Tao Y.; Cremer J.; Elston R.; Davies M.; Baptiste-Brown S.; Han K.; Campbell F.M.; Paff M.; Theodore D.; Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy. J Hepatol 2022,77(4),967-977","journal-title":"J Hepatol"},{"key":"ref=118","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01513-4","author":"Yuen M.F.","year":"2021","unstructured":"Yuen M.F.; Heo J.; Jang J.W.; Yoon J.H.; Kweon Y.O.; Park S.J.; Tami Y.; You S.; Yates P.; Tao Y.; Cremer J.; Campbell F.; Elston R.; Theodore D.; Paff M.; Bennett C.F.; Kwoh T.J.; Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. Nat Med 27(2021), 1725-1734 2021","journal-title":"Nat Med 27(2021), 1725-1734"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1002\/hep.31920","volume":"74","author":"Gane E.","year":"2021","unstructured":"Gane E.; Yuen M.F.; Kim D.J.; Chan H.L.Y.; Surujbally B.; Pavlovic V.; Das S.; Triyatni M.; Kazma R.; Grippo J.F.; Buatois S.; Lemenuel-Diot A.; Krippendorff B.F.; Mueller H.; Zhang Y.; Kim H.J.; Leerapun A.; Lim T.H.; Lim Y.S.; Tanwandee T.; Kim W.; Cheng W.; Hu T.H.; Wat C.; Clinical study of single-stranded oligonucleotide RO7062931 in healthy volunteers and patients with chronic hepatitis B. Hepatology 2021,74(4),1795-1808","journal-title":"Hepatology"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1096\/fj.13-236372","volume":"28","author":"Curtil C.","year":"2014","unstructured":"Curtil C.; Enache L.S.; Radreau P.; Dron A.G.; Scholt\u00e8s C.; Deloire A.; Roche D.; Lotteau V.; Andr\u00e9 P.; Rami\u00e8re C.; The metabolic sensors FXR\u03b1, PGC\u20101 \u03b1 and SIRT1 cooperatively regulate hepatitis B virus transcription. FASEB J 2014,28(3),1454-1463","journal-title":"FASEB J"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1210\/me.2013-1353","volume":"28","author":"Singh N.","year":"2014","unstructured":"Singh N.; Yadav M.; Singh A.K.; Kumar H.; Dwivedi S.K.D.; Mishra J.S.; Gurjar A.; Manhas A.; Chandra S.; Yadav P.N.; Jagavelu K.; Siddiqi M.I.; Trivedi A.K.; Chattopadhyay N.; Sanyal S.; Synthetic FXR agonist GW4064 is a modulator of multiple G protein-coupled receptors. Mol Endocrinol 2014,28(5),659-673","journal-title":"Mol Endocrinol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3978\/j.issn.2305-5839.2014.12.06","volume":"3","author":"Ali A.H.","year":"2015","unstructured":"Ali A.H.; Carey E.J.; Lindor K.D.; Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med 2015,3(1),5","journal-title":"Ann Transl Med"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s11418-016-0980-6","volume":"70","author":"Xu J.","year":"2016","unstructured":"Xu J.; Gu W.; Li C.; Li X.; Xing G.; Li Y.; Song Y.; Zheng W.; Epigallocatechin gallate inhibits hepatitis B virus via farnesoid X receptor alpha. J Nat Med 2016,70(3),584-591","journal-title":"J Nat Med"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"S690","DOI":"10.1016\/S0168-8278(17)31853-6","volume":"66","author":"Joly S.","year":"2017","unstructured":"Joly S.; Porcherot M.; Radreau P.; Vonderscher J.; Andr\u00e9 P.; Meldrum E.; Arold G.; Van de Wetering de Rooij, J.; Staner, C.; Laveille, C.; Scalfaro, P. The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells. J Hepatol 2017,66(1),S690","journal-title":"J Hepatol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.1073\/pnas.1502400112","volume":"112","author":"Ebert G.","year":"2015","unstructured":"Ebert G.; Allison C.; Preston S.; Cooney J.; Toe J.G.; Stutz M.D.; Ojaimi S.; Baschuk N.; Nachbur U.; Torresi J.; Silke J.; Begley C.G.; Pellegrini M.; Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis. Proc Natl Acad Sci USA 2015,112(18),5803-5808","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1073\/pnas.1502390112","volume":"112","author":"Ebert G.","year":"2015","unstructured":"Ebert G.; Preston S.; Allison C.; Cooney J.; Toe J.G.; Stutz M.D.; Ojaimi S.; Scott H.W.; Baschuk N.; Nachbur U.; Torresi J.; Chin R.; Colledge D.; Li X.; Warner N.; Revill P.; Bowden S.; Silke J.; Begley C.G.; Pellegrini M.; Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus. Proc Natl Acad Sci USA 2015,112(18),5797-5802","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"10462","DOI":"10.3390\/ijms221910462","volume":"22","author":"Kayesh M.E.H.","year":"2021","unstructured":"Kayesh M.E.H.; Kohara M.; Tsukiyama-Kohara K.; Toll-like receptor response to hepatitis B virus infection and potential of tlr agonists as immunomodulators for treating chronic hepatitis B: An overview. Int J Mol Sci 2021,22(19),10462","journal-title":"Int J Mol Sci"},{"key":"ref=128","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2021.105196","volume":"196","author":"Herschke F.","year":"2021","unstructured":"Herschke F.; Li C.; Zhu R.; Han Q.; Wu Q.; Lu Q.; Barale-Thomas E.; De Jonghe S.; Lin T.I.; De Creus A.; JNJ-64794964 (AL-034\/TQ-A3334), a TLR7 agonist, induces sustained anti-HBV activity in AAV\/HBV mice vianon-cytolytic mechanisms. Antiviral Res 2021,196","journal-title":"Antiviral Res"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/cts.12791","volume":"13","author":"Luk A.","year":"2020","unstructured":"Luk A.; Jiang Q.; Glavini K.; Triyatni M.; Zhao N.; Racek T.; Zhu Y.; Grippo J.F.; A single and multiple ascending dose study of toll-like receptor 7 Agonist (RO7020531) in Chinese healthy volunteers. Clin Transl Sci 2020,13(5),985-993","journal-title":"Clin Transl Sci"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/hep.31255","volume":"73","author":"Daffis S.","year":"2021","unstructured":"Daffis S.; Balsitis S.; Chamberlain J.; Zheng J.; Santos R.; Rowe W.; Ramakrishnan D.; Pattabiraman D.; Spurlock S.; Chu R.; Kang D.; Mish M.; Ramirez R.; Li L.; Li B.; Ma S.; Hung M.; Voitenleitner C.; Yon C.; Suresh M.; Menne S.; Cote P.; Delaney W.E.; Mackman R.; Fletcher S.P.; Toll-like receptor 8 agonist GS-9688 induces sustained efficacy in the woodchuck model of chronic hepatitis B. Hepatology 2021,73(1),53-67","journal-title":"Hepatology"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1126\/science.1132998","volume":"314","author":"Pichlmair A.","year":"2006","unstructured":"Pichlmair A.; Schulz O.; Tan C.P.; N\u00e4slund T.I.; Liljestr\u00f6m P.; Weber F.; Reis e Sousa C.; RIG-I-mediated antiviral responses to single-stranded RNA bearing 5\u2032-phosphates. Science 2006,314(5801),997-1001","journal-title":"Science"},{"key":"ref=132","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161313","volume":"11","author":"Korolowicz K.E.","year":"2016","unstructured":"Korolowicz K.E.; Iyer R.P.; Czerwinski S.; Suresh M.; Yang J.; Padmanabhan S.; Sheri A.; Pandey R.K.; Skell J.; Marquis J.K.; Kallakury B.V.; Tucker R.D.; Menne S.; Antiviral efficacy and host innate immunity associated with sb 9200 treatment in the woodchuck model of chronic hepatitis B. PLoS One 2016,11(8)","journal-title":"PLoS One"},{"key":"ref=133","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.42","volume":"6","author":"Ye B.","year":"2015","unstructured":"Ye B.; Liu X.; Li X.; Kong H.; Tian L.; Chen Y.; T-cell exhaustion in chronic hepatitis B infection: Current knowledge and clinical significance. Cell Death Dis 2015,6(3)","journal-title":"Cell Death Dis"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3390\/v12091051","volume":"12","author":"Cai H.","year":"2020","unstructured":"Cai H.; Liu G.; Zhong J.; Zheng K.; Xiao H.; Li C.; Song X.; Li Y.; Xu C.; Wu H.; He Z.; Zhu Q.; Immune checkpoints in viral infections. Viruses 2020,12(9),1051","journal-title":"Viruses"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1128\/JVI.02844-06","volume":"81","author":"Boni C.","year":"2007","unstructured":"Boni C.; Fisicaro P.; Valdatta C.; Amadei B.; Di Vincenzo P.; Giuberti T.; Laccabue D.; Zerbini A.; Cavalli A.; Missale G.; Bertoletti A.; Ferrari C.; Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 2007,81(8),4215-4225","journal-title":"J Virol"},{"key":"ref=136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047648","volume":"7","author":"Nebbia G.","year":"2012","unstructured":"Nebbia G.; Peppa D.; Schurich A.; Khanna P.; Singh H.D.; Cheng Y.; Rosenberg W.; Dusheiko G.; Gilson R.; ChinAleong, J.; Kennedy, P.; Maini, M.K. Upregulation of the Tim-3\/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One 2012,7(10)","journal-title":"PLoS One"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/eji.201141852","volume":"42","author":"Wu W.","year":"2012","unstructured":"Wu W.; Shi Y.; Li S.; Zhang Y.; Liu Y.; Wu Y.; Chen Z.; Blockade of Tim-3 signaling restores the virus-specific CD8 + T-cell response in patients with chronic hepatitis B. Eur J Immunol 2012,42(5),1180-1191","journal-title":"Eur J Immunol"},{"key":"ref=138","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005275","volume":"96","author":"Ye B.","year":"2017","unstructured":"Ye B.; Li X.; Dong Y.; Wang Y.; Tian L.; Lin S.; Liu X.; Kong H.; Chen Y.; Increasing LAG-3 expression suppresses T-cell function in chronic hepatitis B. Medicine 2017,96(1)","journal-title":"Medicine"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"1938-1949.e3, 1949.e1- 1949.e3","DOI":"10.1053\/j.gastro.2008.03.037","volume":"134","author":"Zhang Z.","year":"2008","unstructured":"Zhang Z.; Zhang J.Y.; Wherry E.J.; Jin B.; Xu B.; Zou Z.S.; Zhang S.Y.; Li B.S.; Wang H.F.; Wu H.; Lau G.K.K.; Fu Y.X.; Wang F.S.; Dynamic programmed death 1 expression by virusspecific CD8 T cells correlates with the outcome of acute hepatitis B Gastroenterology 2008,134(7),1938-1949.e3, 1949.e1- 1949.e3","journal-title":"B Gastroenterology"},{"key":"ref=140","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003856","volume":"10","author":"Liu J.","year":"2014","unstructured":"Liu J.; Zhang E.; Ma Z.; Wu W.; Kosinska A.; Zhang X.; M\u00f6ller I.; Seiz P.; Glebe D.; Wang B.; Yang D.; Lu M.; Roggendorf M.; Enhancing virus-specific immunity in vivoby combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog 2014,10(1)","journal-title":"PLoS Pathog"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","volume":"71","author":"Gane E.","year":"2019","unstructured":"Gane E.; Verdon D.J.; Brooks A.E.; Gaggar A.; Nguyen A.H.; Subramanian G.M.; Schwabe C.; Dunbar P.R.; Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. J Hepatol 2019,71(5),900-907","journal-title":"J Hepatol"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s40425-019-0808-5","volume":"7","author":"Zhang X.","year":"2019","unstructured":"Zhang X.; Zhou Y.; Chen C.; Fang W.; Cai X.; Zhang X.; Zhao M.; Zhang B.; Jiang W.; Lin Z.; Ma Y.; Yang Y.; Huang Y.; Zhao H.; Xu R.; Hong S.; Zhang L.; Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. J Immunother Cancer 2019,7(1),322","journal-title":"J Immunother Cancer"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/pathogens10111440","volume":"10","author":"Akbar S.M.F.","year":"2021","unstructured":"Akbar S.M.F.; Al Mahtab M.; Aguilar J.C.; Yoshida O.; Penton E.; Gerardo G.N.; Hiasa Y.; Sustained antiviral and liver protection by a nasal therapeutic vaccine (NASVAC, Containing Both HBsAg and HBcAg) in patients with chronic hepatitis b: 2-year follow-up of phase III clinical trial. Pathogens 2021,10(11),1440","journal-title":"Pathogens"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1136\/gutjnl-2014-308041","volume":"64","author":"Martin P.","year":"2015","unstructured":"Martin P.; Dubois C.; Jacquier E.; Dion S.; Mancini-Bourgine M.; Godon O.; Kratzer R.; Lelu-Santolaria K.; Evlachev A.; Meritet J.F.; Schlesinger Y.; Villeval D.; Strub J.M.; Van Dorsselaer A.; Marchand J.B.; Geist M.; Brandely R.; Findeli A.; Boukhebza H.; Menguy T.; Silvestre N.; Michel M.L.; Inchausp\u00e9 G.; TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice. Gut 2015,64(12),1961-1971","journal-title":"Gut"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1080\/21645515.2019.1651141","volume":"16","author":"Zoulim F.","year":"2020","unstructured":"Zoulim F.; Fournier C.; Habersetzer F.; Sprinzl M.; Pol S.; Coffin C.S.; Leroy V.; Ma M.; Wedemeyer H.; Lohse A.W.; Thimme R.; Lugardon K.; Martin P.; Bastien B.; Sansas B.; Adda N.; Halluard C.; Bendjama K.; Brandely M.; Inchausp\u00e9 G.; Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: A phase 1b placebo-controlled trial. Hum Vaccin Immunother 2020,16(2),388-399","journal-title":"Hum Vaccin Immunother"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","volume":"157","author":"Boni C.","year":"2019","unstructured":"Boni C.; Janssen H.L.A.; Rossi M.; Yoon S.K.; Vecchi A.; Barili V.; Yoshida E.M.; Trinh H.; Rodell T.C.; Laccabue D.; Alfieri A.; Brillo F.; Fisicaro P.; Acerbi G.; Pedrazzi G.; Andreone P.; Cursaro C.; Margotti M.; Santoro R.; Piazzolla V.; Brunetto M.R.; Coco B.; Cavallone D.; Zhao Y.; Joshi A.; Woo J.; Lau A.H.; Gaggar A.; Subramanian G.M.; Massetto B.; Fung S.; Ahn S.H.; Ma X.; Mangia A.; Ferrari C.; Combined GS-4774 and tenofovir therapy can improve HBV-specific t-cell responses in patients with chronic hepatitis. Gastroenterol 2019,157(1),227-241.e7","journal-title":"Gastroenterol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/vaccines8020184","volume":"8","author":"Chinnakannan S.K.","year":"2020","unstructured":"Chinnakannan S.K.; Cargill T.N.; Donnison T.A.; Ansari M.A.; Sebastian S.; Lee L.N.; Hutchings C.; Klenerman P.; Maini M.K.; Evans T.; Barnes E.; The design and development of a multi-hbv antigen encoded in chimpanzee adenoviral and modified vaccinia ankara viral vectors; a novel therapeutic vaccine strategy against HBV. Vaccines 2020,8(2),184","journal-title":"Vaccines"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/cei.13614","volume":"205","author":"Cargill T.","year":"2021","unstructured":"Cargill T.; Barnes E.; Therapeutic vaccination for treatment of chronic hepatitis B. Clin Exp Immunol 2021,205(2),106-118","journal-title":"Clin Exp Immunol"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026623666230413094331","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/215758\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026623666230413094331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T11:34:05Z","timestamp":1695123245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/215758\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":148,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,8,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026623666230413094331","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-10-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}